| Symbol | JAZZ |
|---|---|
| Name | JAZZ PHARMACEUTICALS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | WATERLOO ROAD,FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7, Ireland |
| Telephone | +353 16347800 |
| Fax | — |
| — | |
| Website | https://www.jazzpharmaceuticals.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001232524 |
| Description | Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Additional info from NASDAQ: |
2026-05-05 20:27
Director COZADD BRUCE C 🔴 sold 6.0K shares of Jazz Pharmaceuticals plc (JAZZ) at $203.33 ($1.2M) Transaction Date: May 01, 2026 | Filing ID: 000011
Read more
2026-05-05 20:06
(10% Negative) JAZZ PHARMACEUTICALS PLC (JAZZ) Reports Q2 2026 Financial Results
Read more
2026-05-01 19:44
📋 Bruce C Cozadd (Officer) plans to sell 6K shares of Jazz Pharmaceuticals Plc (at $203.33 each, total $1.2M) Filed: May 01, 2026 | ID: 029296
Read more
2026-04-30 12:20
New Form SCHEDULE 13G - Jazz Pharmaceuticals plc <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000775 <b>Size:</b> 7 KB
Read more
2026-04-21 20:15
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
Read more
2026-04-03 21:09
Director COZADD BRUCE C 🔴 sold 6.0K shares of Jazz Pharmaceuticals plc (JAZZ) at $191.74 ($1.1M) Transaction Date: Apr 01, 2026 | Filing ID: 000009
Read more
2026-04-01 20:15
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Read more
2026-04-01 20:15
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Read more
2026-04-01 20:03
📋 Bruce C Cozadd (Officer) plans to sell 6K shares of Jazz Pharmaceuticals Plc (at $190.50 each, total $1.1M) Filed: Apr 01, 2026 | ID: 022784
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02533115 | EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | — | Secondary AML | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04617002 | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant an… | — | Glioma | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04578444 | An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HE… | — | HER2-Positive Advanced Biliary Tract Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00590915 | Erwinase Master Treatment Protocol | — | Leukemia, Acute Lymphoblastic | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously… | — | Small Cell Lung Cancer | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04943952 | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients W… | — | Acute Lymphoblastic Leukemia | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03134131 | Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High … | — | Glioma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02596997 | Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious … | — | Adenovirus | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05392374 | Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliom… | — | Glioma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02660255 | Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy | — | Epilepsy | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05974293 | A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spec… | Phase2 | NMO Spectrum Disorder | Withdrawn | 2026-12-31 | 2027-09-30 | ClinicalTrials.gov |
| NCT06012929 | A Study of ONC201 for Refractory Meningioma | Phase2 | Meningioma | Withdrawn | 2026-12-01 | 2027-04-01 | ClinicalTrials.gov |
| NCT07533942 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | Phase2 | Meningioma | Not_Yet_Recruiting | 2026-06-01 | 2031-10-16 | ClinicalTrials.gov |
| NCT06924827 | A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol … | Phase4 | Dravet Syndrome (DS) | Not_Yet_Recruiting | 2026-06-01 | 2029-06-01 | ClinicalTrials.gov |
| NCT06738368 | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH… | Phase2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Recruiting | 2026-05-08 | 2028-07-30 | ClinicalTrials.gov |
| NCT07434973 | Stratification and Treatment in Early Psychosis Study - PROMOTE | Phase3 | Clinical High Risk for Psychosis (CHR) | Not_Yet_Recruiting | 2026-05-01 | 2031-12-01 | ClinicalTrials.gov |
| NCT07290985 | AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Ade… | Phase2 | Gastroesophageal Adenocarcinoma | Not_Yet_Recruiting | 2026-05-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer | Phase1 | Small Cell Lung Cancer ( SCLC ) | Not_Yet_Recruiting | 2026-05-01 | 2029-10-01 | ClinicalTrials.gov |
| NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Pa… | Phase2 | Extensive-stage Small-cell Lung Cancer | Not_Yet_Recruiting | 2026-04-25 | 2028-04-30 | ClinicalTrials.gov |
| NCT07377539 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Eff… | Phase1 | Healthy Participants | Recruiting | 2026-02-03 | 2026-07-05 | ClinicalTrials.gov |
| NCT07176312 | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L… | Phase2 | Gastroesophageal Adenocarcinoma | Recruiting | 2026-01-16 | 2029-03-01 | ClinicalTrials.gov |
| NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase2 | Advanced Pheochromocytoma and Paraganglioma | Recruiting | 2026-01-02 | 2028-12-15 | ClinicalTrials.gov |
| NCT07233239 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-O… | Phase1 | Focal Seizures | Recruiting | 2025-11-26 | 2027-11-29 | ClinicalTrials.gov |
| NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Pati… | Phase2 | Non-Small Cell Lung Cancer | Recruiting | 2025-10-30 | 2030-06-24 | ClinicalTrials.gov |
| NCT07278505 | Study of Cannabidiol and Neuroimaging on Stress | Phase1 | Early Life Adversity | Recruiting | 2025-10-28 | 2030-02-28 | ClinicalTrials.gov |
| NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in … | Phase2 | HER2-positive Breast Cancer | Recruiting | 2025-09-24 | 2030-08-01 | ClinicalTrials.gov |
| NCT06113237 | Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex Durin… | — | Maternal Complications | Recruiting | 2025-08-05 | 2033-08-31 | ClinicalTrials.gov |
| NCT06961266 | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of … | Phase1 | Narcolepsy | Terminated | 2025-05-13 | 2026-01-29 | ClinicalTrials.gov |
| NCT06261502 | Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fra… | Phase2 | Fragile X Syndrome | Not_Yet_Recruiting | 2025-05-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT06261450 | Effect of CBD on the Brain | Phase2 | Fragile X Syndrome | Not_Yet_Recruiting | 2025-05-01 | 2027-12-15 | ClinicalTrials.gov |
| NCT05485831 | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: a… | — | Lennox Gastaut Syndrome | Recruiting | 2025-02-24 | 2027-02-01 | ClinicalTrials.gov |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase2 | Breast Cancer | Recruiting | 2025-01-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue S… | Phase1 | Locally Advanced Soft Tissue Sarcoma | Withdrawn | 2024-10-31 | 2027-10-31 | ClinicalTrials.gov |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each i… | Phase3 | Metastatic HER2-positive Breast Cancer | Recruiting | 2024-08-13 | 2030-10-18 | ClinicalTrials.gov |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for… | Phase2 | Transplant-Associated Thrombotic Microangiopathy | Withdrawn | 2024-08-01 | 2027-05-31 | ClinicalTrials.gov |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standa… | Phase3 | Biliary Tract Cancer | Recruiting | 2024-07-19 | 2030-04-01 | ClinicalTrials.gov |
| NCT06043427 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesoph… | Phase2 | Gastroesophageal Adenocarcinoma | Recruiting | 2024-04-16 | 2026-12-31 | ClinicalTrials.gov |
| NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice | — | Acute Myeloid Leukemia (AML) | Completed | 2023-12-07 | 2025-10-23 | ClinicalTrials.gov |
| NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab i… | Phase1 | Advanced Solid Tumor | Recruiting | 2023-11-07 | 2028-05-31 | ClinicalTrials.gov |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Phase1 | Endometrial Cancer | Recruiting | 2023-10-23 | 2028-07-31 | ClinicalTrials.gov |
| NCT05850676 | Disentangling the Role of Depression in Hypersomnia | — | Hypersomnia | Recruiting | 2023-08-01 | 2026-06-30 | ClinicalTrials.gov |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors | Phase1 | Ewing Sarcoma | Recruiting | 2023-07-27 | 2028-07-30 | ClinicalTrials.gov |
| NCT05875974 | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and … | Phase4 | Idiopathic Hypersomnia | Completed | 2023-07-27 | 2025-03-13 | ClinicalTrials.gov |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab… | Phase1 | Ovarian Cancer | Recruiting | 2023-07-12 | 2026-12-31 | ClinicalTrials.gov |
| NCT05733390 | A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum D… | Phase2 | Irritability Associated With Autism Spectrum Disorder | Withdrawn | 2023-06-30 | 2023-11-09 | ClinicalTrials.gov |
| NCT05864846 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiole… | Phase4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | Completed | 2023-06-29 | 2026-04-06 | ClinicalTrials.gov |
| NCT05869773 | A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood P… | Phase4 | Narcolepsy | Completed | 2023-06-26 | 2025-03-10 | ClinicalTrials.gov |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants Wi… | Phase1 | Refractory Ewing Sarcoma | Recruiting | 2023-05-23 | 2028-04-20 | ClinicalTrials.gov |
| NCT04990102 | Phase IB/II of CPX-351 for Relapse Prevention in AML | Phase1 | Acute Myeloid Leukemia (AML) in Remission | Recruiting | 2023-05-22 | 2026-12-01 | ClinicalTrials.gov |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Fi… | Phase2 | Metastatic Cancer | Withdrawn | 2023-05-08 | 2028-11-01 | ClinicalTrials.gov |
| NCT05260528 | CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adve… | Phase2 | Acute Myeloid Leukemia | Recruiting | 2023-05-03 | 2030-02-02 | ClinicalTrials.gov |
| NCT05772429 | Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France … | — | Seizures | Active_Not_Recruiting | 2023-04-17 | 2026-07-01 | ClinicalTrials.gov |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Phase1 | Acute Myeloid Leukemia | Recruiting | 2023-02-16 | 2027-04-01 | ClinicalTrials.gov |
| NCT05629702 | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids | Phase2 | Glioblastoma | Recruiting | 2023-02-03 | 2027-04-01 | ClinicalTrials.gov |
| NCT05720494 | A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Ph… | Phase1 | Healthy Participants | Completed | 2023-01-26 | 2023-09-29 | ClinicalTrials.gov |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Stud… | Phase3 | H3 K27M | Recruiting | 2023-01-23 | 2028-06-01 | ClinicalTrials.gov |
| NCT05656248 | Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neop… | Phase2 | Myeloid Neoplasm | Active_Not_Recruiting | 2023-01-17 | 2028-08-01 | ClinicalTrials.gov |
| NCT05631327 | A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors | Phase1 | Advanced Solid Tumor | Terminated | 2022-12-19 | 2024-04-24 | ClinicalTrials.gov |
| NCT05642442 | A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in P… | Phase2 | Parkinson Disease | Completed | 2022-12-01 | 2024-11-11 | ClinicalTrials.gov |
| NCT05651152 | A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmaco… | Phase1 | Healthy Participants | Completed | 2022-11-28 | 2023-11-15 | ClinicalTrials.gov |
| NCT05288283 | Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With … | Phase3 | Seizures Associated With EMAS | Terminated | 2022-10-31 | 2023-09-28 | ClinicalTrials.gov |
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastat… | Phase1 | Advanced Cancer | Recruiting | 2022-10-10 | 2028-04-01 | ClinicalTrials.gov |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | Phase3 | Diffuse Intrinsic Pontine Glioma | Recruiting | 2022-09-29 | 2031-09-01 | ClinicalTrials.gov |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Sma… | Phase1 | Extensive Stage Lung Small Cell Carcinoma | Recruiting | 2022-07-27 | 2027-07-28 | ClinicalTrials.gov |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Withdrawn | 2022-07-05 | 2032-08-01 | ClinicalTrials.gov |
| NCT05229588 | Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA … | Phase2 | Gastrointestinal Malignancies | Completed | 2022-06-14 | 2025-08-04 | ClinicalTrials.gov |
| NCT05126433 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tum… | Phase2 | Advanced Solid Tumor | Terminated | 2022-03-03 | 2023-12-20 | ClinicalTrials.gov |
| NCT05024552 | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | Phase1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | Recruiting | 2022-02-25 | 2027-03-01 | ClinicalTrials.gov |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | Phase1 | Advanced Soft-tissue Sarcoma | Active_Not_Recruiting | 2022-02-04 | 2027-07-01 | ClinicalTrials.gov |
| NCT05169307 | CPX-351 Real-World Effectiveness and Safety Study | — | Acute Myeloid Leukemia | Completed | 2022-01-14 | 2022-06-15 | ClinicalTrials.gov |
| NCT05178316 | A Study of JZP150 in Adults With Posttraumatic Stress Disorder | Phase2 | Post Traumatic Stress Disorder | Completed | 2021-12-29 | 2023-12-05 | ClinicalTrials.gov |
| NCT05122650 | A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults … | Phase2 | Essential Tremor | Completed | 2021-12-06 | 2024-05-30 | ClinicalTrials.gov |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With … | Phase3 | Small-Cell Lung Cancer | Active_Not_Recruiting | 2021-11-18 | 2026-08-13 | ClinicalTrials.gov |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase2 | Diffuse Intrinsic Pontine Glioma | Recruiting | 2021-10-20 | 2029-06-30 | ClinicalTrials.gov |
| NCT05027139 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advance… | Phase1 | HER2-expressing Cancers | Completed | 2021-09-15 | 2025-09-30 | ClinicalTrials.gov |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and… | Phase1 | Diffuse Midline Glioma (DMG) | Recruiting | 2021-08-23 | 2027-07-31 | ClinicalTrials.gov |
| NCT04984278 | Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of… | Phase3 | Spasticity With Multiple Sclerosis | Terminated | 2021-08-16 | 2022-11-11 | ClinicalTrials.gov |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Gr… | Phase2 | Acute Myeloid Leukemia | Terminated | 2021-08-09 | 2023-08-27 | ClinicalTrials.gov |
| NCT04899050 | Epidiolex in Typical Absence Seizures | Phase4 | Study the Efficacy of Epidiolex for Typical Absence Seizures | Completed | 2021-07-30 | 2023-05-27 | ClinicalTrials.gov |
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Young… | Phase2 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Active_Not_Recruiting | 2021-07-29 | 2027-01-29 | ClinicalTrials.gov |
| NCT05044819 | Assessment of Potential for Chronic Liver Injury in Participants Treated With E… | Phase4 | Lennox Gastaut Syndrome | Active_Not_Recruiting | 2021-07-07 | 2028-03-31 | ClinicalTrials.gov |
| NCT04894591 | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Exten… | — | Extensive-stage Small-cell Lung Cancer | Completed | 2021-06-28 | 2025-06-04 | ClinicalTrials.gov |
| NCT04602936 | Solriamfetol in Binge Eating Disorder | Phase4 | Binge Eating Disorder | Unknown | 2021-06-15 | 2024-12-30 | ClinicalTrials.gov |
| NCT04745026 | Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP4… | Phase2 | Autism Spectrum Disorder | Completed | 2021-05-31 | 2023-12-21 | ClinicalTrials.gov |
| NCT04485104 | Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children Wit… | Phase3 | Seizure in Participants With Tuberous Sclerosis Complex | Terminated | 2021-05-19 | 2025-01-28 | ClinicalTrials.gov |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acut… | Phase3 | Acute Myeloid Leukemia | Terminated | 2021-04-30 | 2022-05-16 | ClinicalTrials.gov |
| NCT04803786 | A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study … | — | Narcolepsy | Completed | 2021-04-09 | 2022-02-24 | ClinicalTrials.gov |
| NCT05055271 | Delphi Consensus Excessive Daytime Sleepiness in OSA | — | Obstructive Sleep Apnea | Completed | 2021-04-01 | 2022-09-12 | ClinicalTrials.gov |
| NCT04794491 | An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy | Phase4 | Narcolepsy | Completed | 2021-03-22 | 2022-11-15 | ClinicalTrials.gov |
| NCT04721691 | Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (… | Phase1 | Electrical Status Epilepticus of Slow-Wave Sleep | Completed | 2021-03-10 | 2024-01-17 | ClinicalTrials.gov |
| NCT04592159 | Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo … | Phase2 | Post-Traumatic Stress Disorder | Withdrawn | 2021-02-01 | 2023-03-01 | ClinicalTrials.gov |
| NCT04652115 | Defibrotide for the Treatment of Severe COVID-19 | Phase2 | Covid19 | Recruiting | 2021-01-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT04657666 | Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measure… | Phase3 | Spasticity in Participants With Multiple Sclerosis | Completed | 2020-12-21 | 2022-05-10 | ClinicalTrials.gov |
| NCT07156435 | Vyxeos® With Clofarabine for Pediatric AML | Phase1 | Relapsed Pediatric AML | Recruiting | 2020-11-06 | 2028-12-31 | ClinicalTrials.gov |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous Syst… | Phase1 | Central Nervous System Neoplasms | Recruiting | 2020-10-26 | 2026-12-01 | ClinicalTrials.gov |
| NCT04899947 | Child and Adolescent Registry for Participants With Narcolepsy | — | Narcolepsy | Recruiting | 2020-10-10 | 2024-10-01 | ClinicalTrials.gov |
| NCT04530604 | Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrom… | Phase1 | COVID | Completed | 2020-10-01 | 2021-04-09 | ClinicalTrials.gov |
| NCT04203498 | Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Pa… | Phase3 | Multiple Sclerosis (MS) | Terminated | 2020-10-01 | 2023-02-28 | ClinicalTrials.gov |
| NCT04133480 | Investigation of Cognitive Outcomes With Cannabidiol Oral Solution | Phase4 | Lennox-Gastaut Syndrome | Withdrawn | 2020-10-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT04421456 | Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Ad… | Phase2 | Schizophrenia | Terminated | 2020-08-18 | 2022-03-16 | ClinicalTrials.gov |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-d… | Phase2 | Acute Myeloid Leukemia, Adult | Terminated | 2020-08-05 | 2022-07-01 | ClinicalTrials.gov |
| NCT04389840 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Resp… | Phase2 | Coronavirus Disease 2019 (COVID-19) | Terminated | 2020-07-08 | 2021-05-20 | ClinicalTrials.gov |
| NCT04224272 | A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients Wit… | Phase2 | HER2+/HR+ Breast Cancer | Completed | 2020-06-10 | 2025-06-30 | ClinicalTrials.gov |
| NCT04195945 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other … | Phase2 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2020-05-27 | 2027-12-31 | ClinicalTrials.gov |
| NCT04323254 | Language of Sleepiness | — | Sleep | Unknown | 2020-03-23 | 2021-03-23 | ClinicalTrials.gov |
| NCT04252586 | A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in P… | Phase3 | Rett Syndrome | Terminated | 2020-02-28 | 2021-06-09 | ClinicalTrials.gov |
| NCT04231851 | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS R… | Phase2 | Acute Myelogenous Leukemia (AML) Due to Therapy | Active_Not_Recruiting | 2020-02-19 | 2027-06-30 | ClinicalTrials.gov |
| NCT04217278 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and M… | Phase2 | Acute Myeloid Leukaemia | Active_Not_Recruiting | 2020-01-27 | 2026-05-01 | ClinicalTrials.gov |
| NCT03849456 | Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults W… | Phase2 | Autism Spectrum Disorder | Terminated | 2020-01-07 | 2020-05-26 | ClinicalTrials.gov |
| NCT04145531 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leuk… | Phase2 | Acute Lymphoblastic Leukemia | Completed | 2019-12-27 | 2022-07-13 | ClinicalTrials.gov |
| NCT04075747 | A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untr… | Phase1 | Acute Myeloid Leukemia | Completed | 2019-12-02 | 2023-09-12 | ClinicalTrials.gov |
| NCT03436953 | A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Di… | Phase2 | Parkinson's Disease | Withdrawn | 2019-12-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT04176042 | Community-Level Daytime Sleepiness: Social-Environmental Determinants, Conseque… | Na | Daytime Sleepiness | Completed | 2019-11-18 | 2020-06-30 | ClinicalTrials.gov |
| NCT04038437 | A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line … | Phase1 | Acute Myeloid Leukemia | Completed | 2019-10-15 | 2022-09-24 | ClinicalTrials.gov |
| NCT04447846 | Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Phase2 | Sturge-Weber Syndrome | Completed | 2019-10-14 | 2022-12-09 | ClinicalTrials.gov |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antige… | Phase2 | DLBCL | Terminated | 2019-10-04 | 2020-09-30 | ClinicalTrials.gov |
| NCT04006925 | Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate | Phase4 | REM Sleep Behavior Disorder | Completed | 2019-09-10 | 2022-02-01 | ClinicalTrials.gov |
| NCT03897127 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX… | Phase3 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2019-09-04 | 2027-06-01 | ClinicalTrials.gov |
| NCT03929666 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy… | Phase2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | Completed | 2019-08-29 | 2025-08-30 | ClinicalTrials.gov |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML | Phase1 | Acute Myeloid Leukemia | Terminated | 2019-08-23 | 2022-09-01 | ClinicalTrials.gov |
| NCT03848832 | Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patien… | Phase3 | Rett Syndrome | Terminated | 2019-07-29 | 2021-01-21 | ClinicalTrials.gov |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myel… | Phase1 | Acute Myelogenous Leukemia | Terminated | 2019-07-18 | 2023-10-25 | ClinicalTrials.gov |
| NCT03202303 | Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (AS… | Phase2 | Autism Spectrum Disorder | Recruiting | 2019-04-12 | 2027-02-01 | ClinicalTrials.gov |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | Phase2 | Recurrent Acute Myeloid Leukemia | Active_Not_Recruiting | 2019-04-12 | 2024-09-01 | ClinicalTrials.gov |
| NCT03865589 | Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obst… | Na | Bone Marrow Transplant Complications | Active_Not_Recruiting | 2019-04-01 | 2027-06-30 | ClinicalTrials.gov |
| NCT03532035 | Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenov… | Phase2 | Adenovirus | Withdrawn | 2018-12-15 | 2019-05-10 | ClinicalTrials.gov |
| NCT03572764 | CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodyspl… | Phase1 | Myelodysplastic Syndromes | Active_Not_Recruiting | 2018-12-14 | 2027-03-25 | ClinicalTrials.gov |
| NCT03533114 | A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of I… | Phase3 | Idiopathic Hypersomnia | Completed | 2018-11-27 | 2020-12-18 | ClinicalTrials.gov |
| NCT03555955 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokin… | Phase1 | Hematologic Malignancy | Completed | 2018-11-20 | 2021-05-26 | ClinicalTrials.gov |
| NCT03526926 | A Post-Marketing Observational Study of VYXEOS™ | — | Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Completed | 2018-10-23 | 2020-06-12 | ClinicalTrials.gov |
| NCT03575325 | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | Phase2 | Lymphoid Leukemia | Completed | 2018-10-11 | 2023-09-14 | ClinicalTrials.gov |
| NCT02718755 | Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients W… | Phase2 | Hematologic Malignancy | Withdrawn | 2018-05-01 | 2022-05-01 | ClinicalTrials.gov |
| NCT03485729 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Phase2 | Endometrial Cancer Recurrent | Terminated | 2018-03-21 | 2023-01-19 | ClinicalTrials.gov |
| NCT03406702 | CX-8998 for Absence Seizures | Phase2 | Epilepsy | Completed | 2018-02-25 | 2019-03-29 | ClinicalTrials.gov |
| NCT03339297 | An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Hos… | Phase2 | Graft-versus-host Disease | Completed | 2018-02-21 | 2020-05-12 | ClinicalTrials.gov |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | Phase1 | Diffuse Intrinsic Pontine Glioma | Terminated | 2018-01-25 | 2023-05-24 | ClinicalTrials.gov |
| NCT03339401 | The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation | Phase2 | Adenovirus | Terminated | 2017-12-22 | 2019-05-10 | ClinicalTrials.gov |
| NCT03295396 | ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | Phase2 | Glioma | Terminated | 2017-10-30 | 2023-07-19 | ClinicalTrials.gov |
| NCT03335267 | Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | Phase2 | Leukemia, Myeloid, Acute | Completed | 2017-10-19 | 2020-05-29 | ClinicalTrials.gov |
| NCT03101241 | A Phase 2 RCT Study of CX-8998 for Essential Tremor | Phase2 | Essential Tremor | Completed | 2017-08-29 | 2018-07-16 | ClinicalTrials.gov |
| NCT02954887 | Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label… | Phase3 | Infantile Spasms | Completed | 2017-05-12 | 2019-06-13 | ClinicalTrials.gov |
| NCT02953548 | Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) | Phase3 | Infantile Spasms | Completed | 2017-04-24 | 2018-05-07 | ClinicalTrials.gov |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2017-04-19 | 2019-12-16 | ClinicalTrials.gov |
| NCT03030599 | A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With … | Phase3 | Narcolepsy With Cataplexy | Completed | 2017-03-14 | 2019-07-10 | ClinicalTrials.gov |
| NCT03037203 | A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-… | Phase2 | Excessive Sleepiness | Completed | 2017-01-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02607904 | An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Be… | Phase2 | Epilepsy | Completed | 2016-12-15 | 2019-05-27 | ClinicalTrials.gov |
| NCT02607891 | A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and… | Phase2 | Epilepsy | Completed | 2016-11-09 | 2018-10-02 | ClinicalTrials.gov |
| NCT02892123 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Phase1 | HER2-expressing Cancers | Completed | 2016-09-30 | 2024-10-31 | ClinicalTrials.gov |
| NCT02851407 | Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in t… | Phase3 | Veno-occlusive Disease | Completed | 2016-09-01 | 2020-10-20 | ClinicalTrials.gov |
| NCT02544750 | An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in … | Phase3 | Tuberous Sclerosis Complex | Completed | 2016-08-31 | 2021-06-11 | ClinicalTrials.gov |
| NCT02873338 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly D… | Phase2 | Acute Myeloid Leukemia | Completed | 2016-08-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT02806895 | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of E… | Phase2 | Obstructive Sleep Apnea | Completed | 2016-07-05 | 2019-05-28 | ClinicalTrials.gov |
| NCT02806908 | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of E… | Phase2 | Narcolepsy | Completed | 2016-06-01 | 2019-05-19 | ClinicalTrials.gov |
| NCT02544763 | A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in … | Phase3 | Tuberous Sclerosis Complex | Completed | 2016-04-06 | 2019-02-26 | ClinicalTrials.gov |
| NCT02564952 | An Open-label Extension Study to Investigate Possible Drug-drug Interactions Be… | Phase2 | Epilepsy | Completed | 2016-03-11 | 2017-06-07 | ClinicalTrials.gov |
| NCT02365610 | A Study of GWP42006 in People With Focal Seizures - Part B | Phase2 | Epilepsy | Completed | 2016-03-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02565108 | A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Be… | Phase2 | Epilepsy | Completed | 2016-01-20 | 2016-07-21 | ClinicalTrials.gov |
| NCT02647190 | Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed … | Phase1 | Acute Lymphoblastic Leukemia (ALL) | Withdrawn | 2016-01-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | Phase2 | Glioblastoma | Terminated | 2016-01-01 | 2023-04-17 | ClinicalTrials.gov |
| NCT02419469 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults Wit… | Phase2 | Leukemia | Terminated | 2015-11-13 | 2017-06-22 | ClinicalTrials.gov |
| NCT02439970 | A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cy… | Phase3 | Cytomegalovirus Disease | Terminated | 2015-09-01 | 2016-01-30 | ClinicalTrials.gov |
| NCT02539823 | Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent He… | Phase2 | Opiate Addiction | Completed | 2015-09-01 | 2017-05-24 | ClinicalTrials.gov |
| NCT02439957 | A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cy… | Phase3 | Cytomegalovirus Disease | Terminated | 2015-09-01 | 2016-07-31 | ClinicalTrials.gov |
| NCT02224560 | Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut S… | Phase3 | Epilepsy | Completed | 2015-06-08 | 2016-05-19 | ClinicalTrials.gov |
| NCT02348593 | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Ex… | Phase3 | Narcolepsy | Completed | 2015-05-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02348619 | "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Exces… | Phase3 | Obstructive Sleep Apnea | Completed | 2015-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02283281 | Anesthetic Premedication With a Cannabis Extract (Cannapremed) | Phase2 | Pain, Postoperative | Unknown | 2015-05-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT02348632 | "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness i… | Phase3 | Narcolepsy | Completed | 2015-05-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02348606 | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Ex… | Phase3 | Obstructive Sleep Apnea | Completed | 2015-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02224690 | A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD)… | Phase3 | Epilepsy | Completed | 2015-04-28 | 2016-03-18 | ClinicalTrials.gov |
| NCT03032016 | European VOD Registry | — | Hepatic Veno-Occlusive Disease | Completed | 2015-04-24 | 2019-07-01 | ClinicalTrials.gov |
| NCT02224703 | GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP4200… | Phase3 | Epilepsy | Completed | 2015-04-13 | 2018-04-09 | ClinicalTrials.gov |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytar… | Phase2 | Acute Myeloid Leukemia (AML) | Withdrawn | 2015-04-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02091375 | Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dr… | Phase3 | Epilepsy | Completed | 2015-03-30 | 2015-11-26 | ClinicalTrials.gov |
| NCT02369471 | A Study of GWP42006 in People With Focal Seizures - Part A | Phase2 | Epilepsy | Completed | 2015-03-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02420080 | A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagno… | — | Adenovirus | Terminated | 2015-02-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02332655 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Phase1 | Sturge-Weber Syndrome | Completed | 2014-12-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT02325011 | An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of… | Phase1 | Healthy Subjects | Completed | 2014-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02091206 | A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With… | Phase2 | Epilepsy | Completed | 2014-10-22 | 2015-03-09 | ClinicalTrials.gov |
| NCT04268966 | An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposur… | Phase2 | Ebola Virus Disease | Withdrawn | 2014-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02221869 | A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pha… | Phase3 | Narcolepsy With Cataplexy | Completed | 2014-10-01 | 2019-01-25 | ClinicalTrials.gov |
| NCT02271347 | An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brinc… | Phase2 | Ebola Virus | Withdrawn | 2014-10-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01812616 | A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozol… | Phase1 | Cancer | Completed | 2014-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02257684 | A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered … | Phase2 | Acute Lymphoblastic Leukemia | Terminated | 2014-09-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02238925 | An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Po… | Phase2 | Acute Myeloid Leukemia (AML) | Completed | 2014-07-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02150928 | An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular E… | Phase2 | Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | Withdrawn | 2014-05-01 | — | ClinicalTrials.gov |
| NCT02087306 | Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early … | Phase3 | Adenovirus Infection | Completed | 2014-03-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02006628 | A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizo… | Phase2 | Schizophrenia | Completed | 2014-02-25 | 2015-01-08 | ClinicalTrials.gov |
| NCT02053272 | A Study of GWP42004 as Add on to Metformin in the Treatment of Participants Wit… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2014-02-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase1 | Advanced Glioblastoma | Withdrawn | 2014-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02167685 | The Chimerix CMX001 Registry | — | Outcomes | Terminated | 2014-01-01 | 2019-05-10 | ClinicalTrials.gov |
| NCT02056782 | A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Completed | 2013-12-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01898520 | A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spast… | Phase3 | Cerebral Palsy | Completed | 2013-12-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01812603 | A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Pati… | Phase1 | Cancer | Completed | 2013-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | Phase1 | Acute Myeloid Leukemia | Completed | 2013-09-01 | 2019-04-01 | ClinicalTrials.gov |
| NCT01886105 | Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk O… | Phase2 | Metastatic Osteosarcoma | Terminated | 2013-08-19 | 2017-06-11 | ClinicalTrials.gov |
| NCT01769170 | A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infectio… | Phase3 | CMV | Completed | 2013-08-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01843634 | Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidati… | Early_Phase1 | Acute Myeloid Leukemia | Completed | 2013-08-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01918735 | A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects | Phase1 | Epilepsy | Completed | 2013-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01888120 | Patient Registry of Intrathecal Ziconotide Management(PRIZM) | — | Patients With Severe Chronic Pain | Completed | 2013-07-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01887301 | Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in P… | Phase1 | Hepatic Impairment | Completed | 2013-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT04285788 | Incidence and Outcomes Associated With the Management of Adenovirus Infections … | — | Adenovirus Infections, Human | Completed | 2013-01-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01696084 | Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreate… | Phase3 | High Risk Acute Myeloid Leukemia | Completed | 2012-12-13 | 2015-12-31 | ClinicalTrials.gov |
| NCT03393611 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refracto… | Phase1 | Myelodysplastic Syndromes | Completed | 2012-11-30 | 2021-11-18 | ClinicalTrials.gov |
| NCT01643408 | A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy t… | Phase2 | Acute Lymphoblastic Leukemia | Completed | 2012-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01681121 | A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepi… | Phase2 | Narcolepsy | Completed | 2012-09-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persis… | Phase3 | Pain | Completed | 2012-06-29 | 2015-12-28 | ClinicalTrials.gov |
| NCT01551524 | Phase I Study of mPEG-R-Crisantaspase Given IV | Phase1 | Hematologic Malignancies | Completed | 2012-03-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01964547 | A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosi… | Phase4 | Multiple Sclerosis | Completed | 2012-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01485770 | A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessiv… | Phase2 | Narcolepsy | Completed | 2011-12-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel W… | Phase2 | Metastatic Pancreatic Cancer | Terminated | 2011-11-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01361607 | Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer | Phase3 | Pain | Completed | 2011-05-27 | 2014-11-24 | ClinicalTrials.gov |
| NCT01426295 | Pharmaco-economic Study of a New Medical Device Performed From the Perspective … | Phase2 | Hematologic Disease | Completed | 2011-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT05391724 | Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy … | Phase1 | Hepatic Impairment | Completed | 2011-02-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT02073474 | An Observational Post-Marketing Safety Registry of Sativex® | — | Multiple Sclerosis | Completed | 2011-02-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01337089 | Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjuncti… | Phase3 | Pain | Completed | 2011-01-19 | 2016-01-27 | ClinicalTrials.gov |
| NCT01143181 | Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Cause… | Phase3 | Double-stranded DNA Virus | Completed | 2010-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01241344 | Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease | Phase2 | Adenovirus Disease | Completed | 2010-11-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01217112 | GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes | Phase2 | Dyslipidemias | Completed | 2010-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01161641 | Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary … | Phase1 | Protein Losing Enteropathy | Terminated | 2010-07-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01401140 | Comparing the Protective Effects of Two Cardioplegic Solutions, on Cardiac Meta… | Phase3 | Coronary Artery Stenosis | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01080820 | A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in … | Phase1 | Healthy | Completed | 2010-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00803023 | Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solutio… | Phase3 | Fibromyalgia | Completed | 2010-03-01 | — | ClinicalTrials.gov |
| NCT00793598 | CMX001 in Post-transplant Patients With BK Virus Viruria | Phase1 | Viruria | Completed | 2009-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00942305 | Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoieti… | Phase2 | Cytomegalovirus Infection | Completed | 2009-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00931164 | Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO) | Phase1 | Alternating Hemiplegia of Childhood | Completed | 2009-08-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00875693 | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC… | Phase1 | Acute Myelogenous Leukemia | Completed | 2009-06-02 | 2017-12-27 | ClinicalTrials.gov |
| NCT00901732 | Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy… | Phase1 | Oral Mucositis | Unknown | 2009-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00822094 | Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (A… | Phase2 | Acute Myeloid Leukemia | Completed | 2009-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00788892 | Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | Phase2 | Acute Myeloid Leukemia | Completed | 2008-10-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00780182 | Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers | Phase1 | Healthy | Completed | 2008-10-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00594256 | Sodium Oxybate in Schizophrenia With Insomnia | Phase2 | Schizophrenia | Completed | 2008-05-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00670696 | A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel | Phase4 | Healthy | Withdrawn | 2008-04-01 | — | ClinicalTrials.gov |
| NCT01323569 | Abuse Potential of Sativex | Phase1 | Evaluation of Abuse Potential of Sativex | Completed | 2008-02-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT01323465 | Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the… | Phase1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | Completed | 2008-02-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00681538 | A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms… | Phase3 | Spasticity | Completed | 2008-01-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT01322464 | Study to Assess Food Effect on Sativex Bioavailability | Phase1 | Food Effect | Completed | 2008-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT01322139 | Sativex Thorough QT/QTc Study | Phase1 | Effects of Sativex on ECG | Completed | 2007-12-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00598078 | Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patien… | Phase2 | Essential Tremor | Completed | 2007-12-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00628498 | Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND S… | Phase3 | Hepatic Veno-Occlusive Disease | Completed | 2007-12-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT00594945 | Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures | Phase2 | Epilepsy | Completed | 2007-12-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00702468 | Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in S… | Phase3 | Spasticity | Completed | 2007-11-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00514995 | Sodium Oxybate in the Treatment of Binge Eating Disorder | Phase2 | Binge Eating Disorder | Completed | 2007-08-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00506974 | Enhancing Slow Wave Sleep With Sodium Oxybate | Phase4 | Sleep | Completed | 2007-05-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00498485 | Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome | Phase4 | Chronic Fatigue Syndrome | Terminated | 2007-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00457951 | A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD | Phase2 | Chronic Obstructive Pulmonary Disease | Terminated | 2007-04-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00713817 | A Study to Determine the Maintenance of Effect After Long-term Treatment of Sat… | Phase3 | Pain | Completed | 2007-03-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00423605 | Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyal… | Phase3 | Fibromyalgia | Completed | 2006-12-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00423813 | A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia. | Phase3 | Fibromyalgia | Completed | 2006-12-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00389428 | Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Pat… | Phase1 | Hematologic Neoplasms | Completed | 2006-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00371137 | A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia | Phase3 | Fibromyalgia | Completed | 2006-08-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00361842 | Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In … | Phase2 | Colorectal Neoplasms | Completed | 2006-07-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00358501 | Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hemat… | Phase3 | Severe Hepatic Veno-Occlusive Disease | Completed | 2006-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT00693602 | Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic L… | Phase1 | Acute Lymphoblastic Leukemia | Completed | 2006-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00272948 | Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease… | Phase2 | Hepatic Veno-Occlusive Disease | Completed | 2005-12-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00713323 | A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neu… | Phase3 | Pain | Completed | 2005-10-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00710554 | A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated … | Phase3 | Pain | Completed | 2005-08-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00710424 | A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy | Phase3 | Pain | Completed | 2005-07-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00106860 | A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medicat… | Phase3 | Anxiety Disorder | Completed | 2005-03-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT01599234 | A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity… | Phase3 | Multiple Sclerosis | Completed | 2005-03-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00097708 | Experimental Medication For the Treatment of Generalized Anxiety Disorder | Phase3 | Anxiety Disorder | Completed | 2004-11-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00132873 | Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy | Phase3 | Narcolepsy | Completed | 2004-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00641186 | Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkin… | Phase2 | Parkinson Disease | Completed | 2004-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00087555 | Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Trea… | Phase2 | Fibromyalgia | Completed | 2004-07-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00086281 | Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Ob… | Phase4 | Obstructive Sleep Apnea Syndrome | Completed | 2003-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00066170 | Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Tre… | Phase3 | Narcolepsy | Completed | 2003-04-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00678795 | A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Det… | Phase3 | Detrusor Overactivity | Completed | 2002-08-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT01606202 | A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain D… | Phase3 | Pain | Completed | 2002-07-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00711646 | A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosi… | Phase3 | Spasticity | Completed | 2002-06-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00711880 | A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With A… | Phase3 | Pain | Completed | 2002-05-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00675948 | Study to Compare the Safety and Tolerability of Sativex® in Patients With Cance… | Phase3 | Pain | Completed | 2002-04-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT01604265 | A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple… | Phase3 | Multiple Sclerosis | Completed | 2002-03-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT01606176 | A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pai… | Phase3 | Pain | Completed | 2002-03-01 | 2002-08-01 | ClinicalTrials.gov |
| NCT01606137 | A Study of the Long-term Safety of Sativex Use | Phase3 | Multiple Sclerosis | Completed | 2002-02-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00674609 | A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy | Phase3 | Palliative Care | Completed | 2002-02-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT01606189 | A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to … | Phase3 | Pain | Completed | 2001-12-01 | 2002-09-01 | ClinicalTrials.gov |
| NCT01610687 | A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Ca… | Phase3 | Multiple Sclerosis | Completed | 2001-07-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT01610713 | An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and … | Phase3 | Multiple Sclerosis | Completed | 2001-05-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT01610700 | An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in… | Phase3 | Multiple Sclerosis | Completed | 2001-05-01 | 2002-07-01 | ClinicalTrials.gov |
| NCT00003966 | Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Ce… | Phase2 | Veno-occlusive Disease | Completed | 2000-04-01 | 2006-04-01 | ClinicalTrials.gov |
Total clinical trials: 280
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Vincristine | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Rituximab | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Prednisone | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Positron Emission Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Etoposide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Doxorubicin | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Cyclophosphamide | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | ACTIVE_NOT_RECRUITING | NCT04217278 |
| Track 2 | Other | Approved | Daytime Sleepiness | COMPLETED | NCT04176042 |
| Track 1 | Other | Approved | Daytime Sleepiness | COMPLETED | NCT04176042 |
| Placebo | Other | Phase PHASE2 | Obstructive Sleep Apnea | COMPLETED | NCT02806895 |
| JZP-110 | Other | Phase PHASE2 | Obstructive Sleep Apnea | COMPLETED | NCT02806895 |
| Best Supportive Care | Other | Phase PHASE3 | Veno-occlusive Disease | COMPLETED | NCT02851407 |
| Defibrotide | Other | Phase PHASE3 | Veno-occlusive Disease | COMPLETED | NCT02851407 |
| CPX-351 | Other | Preclinical | Acute Myeloid Leukemia | COMPLETED | NCT05169307 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukemia, Adult | TERMINATED | NCT04425655 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia, Adult | TERMINATED | NCT04425655 |
| GWP42006 | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01918735 |
| Placebo | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01918735 |
| Placebo | Other | Phase PHASE3 | Cerebral Palsy | COMPLETED | NCT01898520 |
| Sativex | Other | Phase PHASE3 | Cerebral Palsy | COMPLETED | NCT01898520 |
| Sativex | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01887301 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01610700 |
| GW-1000-02 | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01610700 |
| Placebo | Other | Phase PHASE4 | Binge Eating Disorder | UNKNOWN | NCT04602936 |
| Solriamfetol | Other | Phase PHASE4 | Binge Eating Disorder | UNKNOWN | NCT04602936 |
| Marinol | Other | Phase PHASE1 | Evaluation of Abuse Potential of Sativex | COMPLETED | NCT01323569 |
| Placebo | Other | Phase PHASE1 | Evaluation of Abuse Potential of Sativex | COMPLETED | NCT01323569 |
| Sativex | Other | Phase PHASE1 | Evaluation of Abuse Potential of Sativex | COMPLETED | NCT01323569 |
| Sativex and omeprazole | Other | Phase PHASE1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | COMPLETED | NCT01323465 |
| Sativex and ketoconazole | Other | Phase PHASE1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | COMPLETED | NCT01323465 |
| Sativex and rifampicin | Other | Phase PHASE1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | COMPLETED | NCT01323465 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05720494 |
| JZP441 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05720494 |
| Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | COMPLETED | NCT05178316 |
| JZP150 | Other | Phase PHASE2 | Post Traumatic Stress Disorder | COMPLETED | NCT05178316 |
| Palliative Radiation Therapy | Drug | Phase PHASE1 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT05244239 |
| Lurbinectedin | Other | Phase PHASE1 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT05244239 |
| Viread | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01080820 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01080820 |
| CMX157 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01080820 |
| Custodiol | Other | Phase PHASE3 | Coronary Artery Stenosis | COMPLETED | NCT01401140 |
| St Thomas | Other | Phase PHASE3 | Coronary Artery Stenosis | COMPLETED | NCT01401140 |
| CMX001 | Other | Phase PHASE2 | Ebola Virus | WITHDRAWN | NCT02271347 |
| mPEG-r-crisantaspase | Other | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT01551524 |
| Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | WITHDRAWN | NCT02150928 |
| Bicarbonate de sodium | Other | Phase PHASE2 | Hematologic Disease | COMPLETED | NCT01426295 |
| Caphosol | Other | Phase PHASE2 | Hematologic Disease | COMPLETED | NCT01426295 |
| Brincidofovir | Other | Preclinical | Adenovirus | TERMINATED | NCT02420080 |
| Ziconotide | Other | Preclinical | Patients With Severe Chronic Pain | COMPLETED | NCT01888120 |
| pegcrisantaspase | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02257684 |
| Erwinia Chrysanthemi asparaginase | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | WITHDRAWN | NCT02647190 |
| CPX-351 | Other | Preclinical | Secondary AML | APPROVED_FOR_MARKETING | NCT02533115 |
| CPX-351 | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02238925 |
| CPX-351 | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | WITHDRAWN | NCT02269579 |
| Thioguanine | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Dexamethasone acetate | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Doxorubicin | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Mercaptopurine | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Cyclophosphamide | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Methotrexate | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Rituximab | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Ofatumumab | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| PEG asparaginase | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Prednisone | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Vincristine | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Daunorubicin | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Cytarabine | Other | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Erwinase | Other | Phase PHASE2 | Hematologic Malignancy | WITHDRAWN | NCT02718755 |
| Cytarabine | Other | Phase PHASE2 | Hematologic Malignancy | WITHDRAWN | NCT02718755 |
| Fludarabine | Other | Phase PHASE2 | Hematologic Malignancy | WITHDRAWN | NCT02718755 |
| Xyrem | Other | Phase PHASE3 | Narcolepsy With Cataplexy | COMPLETED | NCT02221869 |
| CMX001 | Other | Preclinical | Outcomes | TERMINATED | NCT02167685 |
| JZP-110 | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT02348632 |
| Placebo oral tablet | Other | Phase PHASE3 | Obstructive Sleep Apnea | COMPLETED | NCT02348606 |
| JZP-110 | Other | Phase PHASE3 | Obstructive Sleep Apnea | COMPLETED | NCT02348606 |
| Placebo oral tablet | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT02348593 |
| JZP-110 | Other | Phase PHASE3 | Narcolepsy | COMPLETED | NCT02348593 |
| JZP-110 | Other | Phase PHASE3 | Obstructive Sleep Apnea | COMPLETED | NCT02348619 |
| External Beam Radiotherapy | Drug | Phase PHASE2 | Metastatic Osteosarcoma | TERMINATED | NCT01886105 |
| Autologous Stem Cell Infusion | Other | Phase PHASE2 | Metastatic Osteosarcoma | TERMINATED | NCT01886105 |
| Sm-EDTMP | Other | Phase PHASE2 | Metastatic Osteosarcoma | TERMINATED | NCT01886105 |
| Placebo | Other | Phase PHASE2 | Excessive Sleepiness | COMPLETED | NCT03037203 |
| JZP-110 | Other | Phase PHASE2 | Excessive Sleepiness | COMPLETED | NCT03037203 |
| Brincidofovir | Other | Phase PHASE2 | Ebola Virus Disease | WITHDRAWN | NCT04268966 |
| Lurbinectedin | Other | Preclinical | Small Cell Lung Cancer | APPROVED_FOR_MARKETING | NCT04291937 |
| CPX-351 | Other | Preclinical | Acute Myeloid Leukemia With Myelodysplasia-Related Changes | COMPLETED | NCT03526926 |
| 7+3 (cytarabine and daunorubicin) | Other | Phase PHASE3 | High Risk Acute Myeloid Leukemia | COMPLETED | NCT01696084 |
| CPX-351 | Other | Phase PHASE3 | High Risk Acute Myeloid Leukemia | COMPLETED | NCT01696084 |
| CPX-351 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT01943682 |
| Placebo | Other | Phase PHASE3 | Narcolepsy With Cataplexy | COMPLETED | NCT03030599 |
| JZP-258 | Other | Phase PHASE3 | Narcolepsy With Cataplexy | COMPLETED | NCT03030599 |
| Placebo | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT02806908 |
| JZP-110 | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT02806908 |
| Brincidofovir | Other | Phase PHASE2 | Adenovirus | TERMINATED | NCT03339401 |
| Standard of Care | Other | Phase PHASE2 | Adenovirus | TERMINATED | NCT03339401 |
| ONC201 | Other | Phase PHASE1 | Advanced Glioblastoma | WITHDRAWN | NCT02038699 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT03436953 |
| CX-8998 | Other | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT03436953 |
| Placebo | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT01681121 |
| ADX-N05 | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT01681121 |
| asparaginase Erwinia chrysanthemi | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT01643408 |
| Placebo | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT01485770 |
| ADX-N05 | Other | Phase PHASE2 | Narcolepsy | COMPLETED | NCT01485770 |
| Valganciclovir | Other | Phase PHASE3 | Cytomegalovirus Disease | TERMINATED | NCT02439970 |
| Brincidofovir | Other | Phase PHASE3 | Cytomegalovirus Disease | TERMINATED | NCT02439970 |
| Valganciclovir | Other | Phase PHASE3 | Cytomegalovirus Disease | TERMINATED | NCT02439957 |
| Brincidofovir | Other | Phase PHASE3 | Cytomegalovirus Disease | TERMINATED | NCT02439957 |
| Standard of Care | Other | Phase PHASE2 | Adenovirus | WITHDRAWN | NCT03532035 |
| Brincidofovir | Other | Phase PHASE2 | Adenovirus | WITHDRAWN | NCT03532035 |
| Placebo | Other | Phase PHASE3 | CMV | COMPLETED | NCT01769170 |
| Brincidofovir | Other | Phase PHASE3 | CMV | COMPLETED | NCT01769170 |
| Placebo | Other | Phase PHASE2 | Adenovirus Disease | COMPLETED | NCT01241344 |
| Brincidofovir | Other | Phase PHASE2 | Adenovirus Disease | COMPLETED | NCT01241344 |
| CPX-351 | Other | Phase PHASE1 | Hematologic Malignancy | COMPLETED | NCT03555955 |
| Asparaginase Erwinia Chrysanthemi (recombinant) | Other | Preclinical | Acute Lymphoblastic Leukemia | APPROVED_FOR_MARKETING | NCT04943952 |
| Brincidofovir | Other | Phase PHASE3 | Double-stranded DNA Virus | COMPLETED | NCT01143181 |
| Brincidofovir | Other | Phase PHASE3 | Adenovirus Infection | COMPLETED | NCT02087306 |
| Standard of Care | Other | Phase PHASE2 | Graft-versus-host Disease | COMPLETED | NCT03339297 |
| Defibrotide | Other | Phase PHASE2 | Graft-versus-host Disease | COMPLETED | NCT03339297 |
| ODSH | Other | Phase EARLY_PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT01843634 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT03101241 |
| CX-8998 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT03101241 |
| Placebo Oral Solution | Other | Phase PHASE3 | Idiopathic Hypersomnia | COMPLETED | NCT03533114 |
| JZP-258 | Other | Phase PHASE3 | Idiopathic Hypersomnia | COMPLETED | NCT03533114 |
| ODSH at 0.250 mg/kg/h | Other | Phase PHASE1 | Protein Losing Enteropathy | TERMINATED | NCT01161641 |
| ODSH at 0.375 mg/kg/h | Other | Phase PHASE1 | Protein Losing Enteropathy | TERMINATED | NCT01161641 |
| ODSH at 0.125 mg/kg/h | Other | Phase PHASE1 | Protein Losing Enteropathy | TERMINATED | NCT01161641 |
| Defibrotide | Other | Phase PHASE2 | DLBCL | TERMINATED | NCT03954106 |
| Cannabidiol | Other | Phase PHASE1 | Sturge-Weber Syndrome | COMPLETED | NCT02332655 |
| ONC201 | Other | Preclinical | Glioma | NO_LONGER_AVAILABLE | NCT03134131 |
| Brincidofovir | Other | Preclinical | Adenovirus | NO_LONGER_AVAILABLE | NCT02596997 |
| ONC201 | Other | Preclinical | Glioma | NO_LONGER_AVAILABLE | NCT05392374 |
| CMX001 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05391724 |
| Placebo | Other | Phase PHASE2 | Post-Traumatic Stress Disorder | WITHDRAWN | NCT04592159 |
| Nabiximols | Other | Phase PHASE2 | Post-Traumatic Stress Disorder | WITHDRAWN | NCT04592159 |
| Dociparstat | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | TERMINATED | NCT01461915 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | TERMINATED | NCT01461915 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | TERMINATED | NCT01461915 |
| Transition from Xyrem to Xywav | Other | Preclinical | Narcolepsy | COMPLETED | NCT04803786 |
| GWP42003-P | Other | Phase PHASE3 | Tuberous Sclerosis Complex | COMPLETED | NCT02544750 |
| GWP42003-P | Other | Phase PHASE3 | Rett Syndrome | TERMINATED | NCT04252586 |
| Placebo | Other | Phase PHASE2 | Coronavirus Disease 2019 (COVID-19) | TERMINATED | NCT04389840 |
| Dociparstat sodium | Other | Phase PHASE2 | Coronavirus Disease 2019 (COVID-19) | TERMINATED | NCT04389840 |
| GWP42003-P | Other | Phase PHASE4 | Lennox-Gastaut Syndrome | WITHDRAWN | NCT04133480 |
| Control (placebo) | Other | Phase PHASE2 | Opiate Addiction | COMPLETED | NCT02539823 |
| CBD 800 mg | Other | Phase PHASE2 | Opiate Addiction | COMPLETED | NCT02539823 |
| CBD 400 mg | Other | Phase PHASE2 | Opiate Addiction | COMPLETED | NCT02539823 |
| GWP42006 | Other | Phase PHASE2 | Autism Spectrum Disorder | TERMINATED | NCT03849456 |
| Placebo | Other | Phase PHASE3 | Rett Syndrome | TERMINATED | NCT03848832 |
| GWP42003-P | Other | Phase PHASE3 | Rett Syndrome | TERMINATED | NCT03848832 |
| GWP42003-P | Other | Phase PHASE3 | Infantile Spasms | COMPLETED | NCT02954887 |
| GWP42003-P | Other | Phase PHASE3 | Infantile Spasms | COMPLETED | NCT02953548 |
| CX-8998 | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT03406702 |
| Clobazam | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02565108 |
| Placebo | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02565108 |
| GWP42003-P 20 mg/kg/Day Dose | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02565108 |
| Clobazam | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02564952 |
| GWP42003-P | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02564952 |
| Placebo | Other | Phase PHASE3 | Tuberous Sclerosis Complex | COMPLETED | NCT02544763 |
| GWP42003-P | Other | Phase PHASE3 | Tuberous Sclerosis Complex | COMPLETED | NCT02544763 |
| Placebo Control | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224703 |
| GWP42003-P | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224703 |
| Placebo | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224690 |
| GWP42003-P 20 mg/kg/day Dose | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224690 |
| Placebo control | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224560 |
| GWP42003-P | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224560 |
| Placebo control | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02091375 |
| GWP42003-P 20 mg/kg/day Dose | Other | Phase PHASE3 | Epilepsy | COMPLETED | NCT02091375 |
| GWP42003-P 20 mg/kg/day Dose | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02091206 |
| GWP42003-P 10 mg/kg/day Dose | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02091206 |
| Placebo control | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02091206 |
| GWP42003-P 5 mg/kg/day Dose | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02091206 |
| GWP42003 | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02006628 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02006628 |
| Placebo | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT01217112 |
| GWP42004 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT01217112 |
| GWP42003 | Other | Phase PHASE2 | Dyslipidemias | COMPLETED | NCT01217112 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04038437 |
| CPX-351 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04038437 |
| GWP42003-P | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02607904 |
| Placebo | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02607891 |
| GWP42003-P | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02607891 |
| Placebo | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02369471 |
| GWP42006 | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02369471 |
| Placebo Control | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02365610 |
| GWP42006 | Other | Phase PHASE2 | Epilepsy | COMPLETED | NCT02365610 |
| Sativex® and fluconazole concomitantly (Treatment B) | Drug | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02325011 |
| Sativex® (Treatment A) | Drug | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02325011 |
| Sativex® | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02073474 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02053272 |
| GWP42004 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02053272 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01812616 |
| Sativex | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01812616 |
| Sativex | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01812603 |
| Haplo-Cord Stem Cell Transplantation | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| Rabbit Anti-Human T-Lymphocyte Globulin | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| Melphalan | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| Fludarabine | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| CPX-351 | Other | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| GW-1000-02 | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01610713 |
| GW-1000-02 | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01610687 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606202 |
| GW-1000-02 | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606202 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606189 |
| GW-2000-02 | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606189 |
| GW-1000-02 | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606189 |
| Placebo | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606176 |
| GW-1000-02 | Other | Phase PHASE3 | Pain | COMPLETED | NCT01606176 |
| Sativex | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01604265 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01604265 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01964547 |
| Sativex | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01964547 |
| Dociparstat sodium | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02056782 |
| Gemtuzumab Ozogamicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT03878927 |
| CPX-351 | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT03878927 |
| Sativex | Other | Phase PHASE1 | Food Effect | COMPLETED | NCT01322464 |
| Placebo spray and moxifloxacin | Other | Phase PHASE1 | Effects of Sativex on ECG | COMPLETED | NCT01322139 |
| Sativex spray and oral moxifloxacin placebo | Other | Phase PHASE1 | Effects of Sativex on ECG | COMPLETED | NCT01322139 |
| Placebo spray and oral moxifloxacin placebo | Other | Phase PHASE1 | Effects of Sativex on ECG | COMPLETED | NCT01322139 |
| Placebo (GA-0034) | Other | Phase PHASE3 | Pain | COMPLETED | NCT01424566 |
| Nabiximols | Other | Phase PHASE3 | Pain | COMPLETED | NCT01424566 |
| Placebo (GA-0034) | Other | Phase PHASE3 | Pain | COMPLETED | NCT01361607 |
| Nabiximols | Other | Phase PHASE3 | Pain | COMPLETED | NCT01361607 |
| Nabiximols | Other | Phase PHASE3 | Pain | COMPLETED | NCT01337089 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01599234 |
| Sativex | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01599234 |
| GW-1000-02 | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01606137 |
| Defibrotide | Other | Phase PHASE1 | COVID | COMPLETED | NCT04530604 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Thiotepa | Other | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Busulphan | Other | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Vyxeos | Other | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Placebo | Other | Phase PHASE4 | REM Sleep Behavior Disorder | COMPLETED | NCT04006925 |
| Sodium Oxybate | Other | Phase PHASE4 | REM Sleep Behavior Disorder | COMPLETED | NCT04006925 |
| Cannabidiol | Other | Phase PHASE2 | Sturge-Weber Syndrome | COMPLETED | NCT04447846 |
| Placebo | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT04421456 |
| GWP42003-P | Other | Phase PHASE2 | Schizophrenia | TERMINATED | NCT04421456 |
| Cannabidiol (Epidiolex) | Other | Phase PHASE4 | Study the Efficacy of Epidiolex for Typical Absence Seizures | COMPLETED | NCT04899050 |
| Placebo | Other | Phase PHASE3 | Spasticity in Participants With Multiple Sclerosis | COMPLETED | NCT04657666 |
| Nabiximols | Other | Phase PHASE3 | Spasticity in Participants With Multiple Sclerosis | COMPLETED | NCT04657666 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02873338 |
| Idarubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02873338 |
| Dociparstat sodium | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT02873338 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Recurrent Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03825796 |
| Enasidenib Mesylate | Other | Phase PHASE2 | Recurrent Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03825796 |
| Cannabidiol | Other | Preclinical | Epilepsy | APPROVED_FOR_MARKETING | NCT02660255 |
| Enasidenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04075747 |
| Midostaurin | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04075747 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04075747 |
| CPX-351 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04075747 |
| IV JZP-458 | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04145531 |
| IM JZP-458 | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04145531 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE1 | Acute Myelogenous Leukemia | TERMINATED | NCT03904251 |
| Gemtuzumab Ozogamicin | Other | Phase PHASE1 | Acute Myelogenous Leukemia | TERMINATED | NCT03904251 |
| JZP-258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT04794491 |
| CPX-351 | Other | Phase PHASE2 | Leukemia, Myeloid, Acute | COMPLETED | NCT03335267 |
| Dummy oromucosal | Other | Phase PHASE2 | Pain, Postoperative | UNKNOWN | NCT02283281 |
| Tetrahydrocannabinol | Other | Phase PHASE2 | Pain, Postoperative | UNKNOWN | NCT02283281 |
| Control | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04571645 |
| Dociparstat | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04571645 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis (MS) | TERMINATED | NCT04203498 |
| Nabiximols | Other | Phase PHASE3 | Multiple Sclerosis (MS) | TERMINATED | NCT04203498 |
| Defibrotide | Other | Phase PHASE2 | Covid19 | RECRUITING | NCT04652115 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | TERMINATED | NCT04526288 |
| Allogeneic Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Acute Myeloid Leukemia | TERMINATED | NCT04526288 |
| JZP341 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05631327 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT02863991 |
| ONC201 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT02863991 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05651152 |
| JZP441 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05651152 |
| avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin | Drug | Phase PHASE2 | Metastatic Cancer | WITHDRAWN | NCT05574504 |
| Defibrotide | Other | Phase PHASE2 | Transplant-Associated Thrombotic Microangiopathy | WITHDRAWN | NCT06182410 |
| CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Fludarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Melphalan | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Busulfan | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Midostaurin | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| CPX-351 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Placebo | Other | Phase PHASE2 | Irritability Associated With Autism Spectrum Disorder | WITHDRAWN | NCT05733390 |
| JZP541 | Other | Phase PHASE2 | Irritability Associated With Autism Spectrum Disorder | WITHDRAWN | NCT05733390 |
| Non-investigational surgery | Procedure | Phase PHASE1 | Locally Advanced Soft Tissue Sarcoma | WITHDRAWN | NCT06217536 |
| Radiotherapy | Drug | Phase PHASE1 | Locally Advanced Soft Tissue Sarcoma | WITHDRAWN | NCT06217536 |
| Lurbinectedin | Other | Phase PHASE1 | Locally Advanced Soft Tissue Sarcoma | WITHDRAWN | NCT06217536 |
| Tucatinib | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT02892123 |
| Vinorelbine | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT02892123 |
| Capecitabine | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT02892123 |
| Paclitaxel | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT02892123 |
| ZW25 (Zanidatamab) | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT02892123 |
| Placebo | Other | Phase PHASE3 | Spasticity With Multiple Sclerosis | TERMINATED | NCT04984278 |
| Nabiximols | Other | Phase PHASE3 | Spasticity With Multiple Sclerosis | TERMINATED | NCT04984278 |
| CPX-351 | Other | Phase PHASE2 | Lymphoid Leukemia | COMPLETED | NCT03575325 |
| Dordaviprone (ONC201) | Other | Phase PHASE2 | Endometrial Cancer Recurrent | TERMINATED | NCT03485729 |
| Dordaviprone (ONC201) | Other | Phase PHASE2 | Glioblastoma | TERMINATED | NCT02525692 |
| Placebo | Other | Phase PHASE3 | Seizures Associated With EMAS | TERMINATED | NCT05288283 |
| GWP42003-P | Other | Phase PHASE3 | Seizures Associated With EMAS | TERMINATED | NCT05288283 |
| Dordaviprone (ONC201) | Other | Phase PHASE1 | Diffuse Intrinsic Pontine Glioma | TERMINATED | NCT03416530 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | NOT_YET_RECRUITING | NCT06261502 |
| CBD Oral Solution | Other | Phase PHASE2 | Fragile X Syndrome | NOT_YET_RECRUITING | NCT06261502 |
| Placebo | Other | Phase PHASE2 | Fragile X Syndrome | NOT_YET_RECRUITING | NCT06261450 |
| CBD Oral Solution (eCBD system Target) | Other | Phase PHASE2 | Fragile X Syndrome | NOT_YET_RECRUITING | NCT06261450 |
| Lurbinectedin | Other | Phase PHASE2 | Advanced Solid Tumor | TERMINATED | NCT05126433 |
| Placebo | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT04745026 |
| GWP42003-P | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT04745026 |
| Epidiolex | Other | Preclinical | Seizures | ACTIVE_NOT_RECRUITING | NCT05772429 |
| Zanidatamab | Other | Preclinical | HER2-Positive Advanced Biliary Tract Cancer | NO_LONGER_AVAILABLE | NCT04578444 |
| Placebo | Other | Phase PHASE1 | Electrical Status Epilepticus of Slow-Wave Sleep | COMPLETED | NCT04721691 |
| Epidiolex 100 mg/mL Oral Solution | Other | Phase PHASE1 | Electrical Status Epilepticus of Slow-Wave Sleep | COMPLETED | NCT04721691 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Sleep study | Other | Preclinical | Hypersomnia | RECRUITING | NCT05850676 |
| JZP258 (XYWAV) | Other | Phase PHASE4 | Idiopathic Hypersomnia | COMPLETED | NCT05875974 |
| CPX-351 | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03897127 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03897127 |
| Cytarabine | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03897127 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05122650 |
| JZP385 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05122650 |
| Dordaviprone (ONC201) | Other | Phase PHASE2 | Glioma | TERMINATED | NCT03295396 |
| Fulvestrant | Other | Phase PHASE2 | HER2+/HR+ Breast Cancer | COMPLETED | NCT04224272 |
| Palbociclib | Other | Phase PHASE2 | HER2+/HR+ Breast Cancer | COMPLETED | NCT04224272 |
| ZW25 (Zanidatamab) | Other | Phase PHASE2 | HER2+/HR+ Breast Cancer | COMPLETED | NCT04224272 |
| Lurbinectedin 4 MG Injection [Zepzelca] | Other | Phase PHASE2 | Gastrointestinal Malignancies | COMPLETED | NCT05229588 |
| ONC201 (dordaviprone) | Other | Preclinical | Glioma | APPROVED_FOR_MARKETING | NCT04617002 |
| Clofarabine | Other | Phase PHASE1 | Relapsed Pediatric AML | RECRUITING | NCT07156435 |
| Vyxeos 44 MG / 100 MG Liposome Injection | Other | Phase PHASE1 | Relapsed Pediatric AML | RECRUITING | NCT07156435 |
| Gemcitabine | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Bevacizumab | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Oxaliplatin | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Leucovorin | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Fluorouracil | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Cisplatin | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Capecitabine | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| ZW25 (Zanidatamab) | Other | Phase PHASE2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | COMPLETED | NCT03929666 |
| Durvalumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Pembrolizumab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemcitabine | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Cisplatin | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Zanidatamab | Other | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| CBD-OS | Other | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07377539 |
| JZP047 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07377539 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| Evorpacept | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT05027139 |
| Zanidatamab | Other | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT05027139 |
| Matched Placebo | Other | Phase PHASE2 | Autism Spectrum Disorder | RECRUITING | NCT03202303 |
| Cannabidivarin | Other | Phase PHASE2 | Autism Spectrum Disorder | RECRUITING | NCT03202303 |
| GWP42003-P | Other | Phase PHASE3 | Seizure in Participants With Tuberous Sclerosis Complex | TERMINATED | NCT04485104 |
| Vyxeos liposomal | Other | Preclinical | Acute Myeloid Leukemia (AML) | COMPLETED | NCT06143839 |
| Vyxeos | Other | Phase PHASE1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | RECRUITING | NCT05024552 |
| Gilteritinib | Other | Phase PHASE1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | RECRUITING | NCT05024552 |
| Placebo | Other | Phase PHASE1 | Early Life Adversity | RECRUITING | NCT07278505 |
| Cannabidiol | Other | Phase PHASE1 | Early Life Adversity | RECRUITING | NCT07278505 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06108050 |
| JZP898 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06108050 |
| DNX-2401 | Other | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| Paxalisib | Other | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| Radiation Therapy | Drug | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| ONC201 | Other | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| ONC206 | Other | Phase PHASE1 | Central Nervous System Neoplasms | RECRUITING | NCT04541082 |
| Zanidatamab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT07192068 |
| Liposome-encapsulated Daunorubicin-Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | ACTIVE_NOT_RECRUITING | NCT04269213 |
| Ultrasound Elastography | Other | Approved | Bone Marrow Transplant Complications | ACTIVE_NOT_RECRUITING | NCT03865589 |
| Suvecaltamide | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05642442 |
| Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05642442 |
| Lurbinectedin | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT05636111 |
| Bevacizumab | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT05636111 |
| Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT05636111 |
| ONC201 | Other | Phase PHASE1 | Endometrial Cancer | RECRUITING | NCT05542407 |
| Atezolizumab | Other | Phase PHASE1 | Endometrial Cancer | RECRUITING | NCT05542407 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Ramucirumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Paclitaxel | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| Nabiximols-matched placebo | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Nabiximols | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Lurbinectedin | Other | Phase PHASE1 | Refractory Ewing Sarcoma | RECRUITING | NCT05734066 |
| mFOLFOX | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT07176312 |
| Pembrolizumab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT07176312 |
| Zanidatamab | Other | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT07176312 |
| Allogeneic Hematopoietic Stem Cell Transplantation | Other | Phase PHASE2 | Myeloid Neoplasm | ACTIVE_NOT_RECRUITING | NCT05656248 |
| MHA | Other | Phase PHASE2 | Myeloid Neoplasm | ACTIVE_NOT_RECRUITING | NCT05656248 |
| CPX-351 | Other | Phase PHASE2 | Myeloid Neoplasm | ACTIVE_NOT_RECRUITING | NCT05656248 |
| Radiotherapy | Drug | Phase PHASE3 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05476939 |
| ONC201 | Other | Phase PHASE3 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05476939 |
| Everolimus | Other | Phase PHASE3 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05476939 |
| Capecitabine | Other | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Vinorelbine | Other | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Eribulin | Other | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Trastuzumab | Other | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Zanidatamab | Other | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Epidiolex 100 mg/mL Oral Solution | Other | Preclinical | Lennox Gastaut Syndrome | RECRUITING | NCT05485831 |
| ONC206: Dose 2 | Other | Phase PHASE2 | Advanced Pheochromocytoma and Paraganglioma | RECRUITING | NCT07282587 |
| ONC206: Dose 1 | Other | Phase PHASE2 | Advanced Pheochromocytoma and Paraganglioma | RECRUITING | NCT07282587 |
| ONC206 | Other | Phase PHASE2 | Advanced Pheochromocytoma and Paraganglioma | RECRUITING | NCT07282587 |
| Gemtuzumab Ozogamicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05558124 |
| Vyxeos | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05558124 |
| Zepzelca | Other | Preclinical | Extensive-stage Small-cell Lung Cancer | COMPLETED | NCT04894591 |
| CPX-351 | Other | Phase PHASE2 | Acute Myelogenous Leukemia (AML) Due to Therapy | ACTIVE_NOT_RECRUITING | NCT04231851 |
| Glasdegib | Other | Phase PHASE2 | Acute Myelogenous Leukemia (AML) Due to Therapy | ACTIVE_NOT_RECRUITING | NCT04231851 |
| Etoposide | Other | Phase PHASE3 | Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05091567 |
| Carboplatin | Other | Phase PHASE3 | Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05091567 |
| Lurbinectedin | Other | Phase PHASE3 | Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05091567 |
| Atezolizumab | Other | Phase PHASE3 | Small-Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05091567 |
| Optional Proton (1H) MR spectroscopy (MRS) | Other | Phase PHASE1 | Diffuse Midline Glioma (DMG) | RECRUITING | NCT04732065 |
| Standard of Care Radiation Therapy | Drug | Phase PHASE1 | Diffuse Midline Glioma (DMG) | RECRUITING | NCT04732065 |
| ONC206 | Other | Phase PHASE1 | Diffuse Midline Glioma (DMG) | RECRUITING | NCT04732065 |
| CPX-351 | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) in Remission | RECRUITING | NCT04990102 |
| CPX-315 | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05260528 |
| Cytarabine and Idarubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05260528 |
| Lurbinectedin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT05918640 |
| Matching Placebo | Other | Phase PHASE1 | Narcolepsy | TERMINATED | NCT06961266 |
| JZP441 | Other | Phase PHASE1 | Narcolepsy | TERMINATED | NCT06961266 |
| Zanidatamab | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT06695845 |
| Epidiolex | Other | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| Doxorubicin | Other | Phase PHASE1 | Advanced Soft-tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT05099666 |
| Lurbinectedin | Other | Phase PHASE1 | Advanced Soft-tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT05099666 |
| Research bone marrow aspirate | Other | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| Research blood draw | Other | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| Research skin biopsy | Other | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| CPX-351 | Other | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) + Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Lurbinectedin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Pertuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Carboplatin | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Paclitaxel | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Zanidatamab | Other | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| Cannabidiol Oral Solution [Epidiolex] | Other | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | COMPLETED | NCT05864846 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP258 | Other | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| JZP815 | Other | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| Cannabidiol | Other | Phase PHASE4 | Lennox Gastaut Syndrome | ACTIVE_NOT_RECRUITING | NCT05044819 |
| Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) + Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| JZP3507 | Other | Phase PHASE2 | Meningioma | NOT_YET_RECRUITING | NCT07533942 |
| Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) + Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| JZP3507 | Other | Phase PHASE2 | Meningioma | NOT_YET_RECRUITING | NCT07533942 |
| Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) + Placebo | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| Dordaviprone (ONC201) | Other | Phase PHASE3 | H3 K27M | RECRUITING | NCT05580562 |
| JZP3507 | Other | Phase PHASE2 | Meningioma | NOT_YET_RECRUITING | NCT07533942 |
| JZP3507 | Other | Phase PHASE2 | Meningioma | NOT_YET_RECRUITING | NCT07533942 |
| JZP047 | DRUG | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07377539 |
| Tislelizumab | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | NOT_YET_RECRUITING | NCT07290985 |
| ONC206: Dose 2 | DRUG | Phase PHASE2 | Advanced Pheochromocytoma and Paraganglioma | RECRUITING | NCT07282587 |
| ONC206: Dose 1 | DRUG | Phase PHASE2 | Advanced Pheochromocytoma and Paraganglioma | RECRUITING | NCT07282587 |
| CBD-OS | DRUG | Phase PHASE1 | Focal Seizures | RECRUITING | NCT07233239 |
| mFOLFOX | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT07176312 |
| Clofarabine | DRUG | Phase PHASE1 | Relapsed Pediatric AML | RECRUITING | NCT07156435 |
| Vyxeos 44 MG / 100 MG Liposome Injection | DRUG | Phase PHASE1 | Relapsed Pediatric AML | RECRUITING | NCT07156435 |
| Osimertinib | DRUG | Phase PHASE1 | Small Cell Lung Cancer ( SCLC ) | NOT_YET_RECRUITING | NCT07153055 |
| Pertuzumab | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Docetaxel | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Matching Placebo | DRUG | Phase PHASE1 | Narcolepsy | TERMINATED | NCT06961266 |
| Positron Emission Tomography | PROCEDURE | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Pegfilgrastim | BIOLOGICAL | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Filgrastim | BIOLOGICAL | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Computed Tomography | PROCEDURE | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Bone Marrow Collection | PROCEDURE | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Asparaginase Erwinia chrysanthemi | DRUG | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Eribulin | DRUG | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Trastuzumab | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Durvalumab | DRUG | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| CBD Oral Solution | DRUG | Phase PHASE2 | Fragile X Syndrome | NOT_YET_RECRUITING | NCT06261502 |
| CBD Oral Solution (eCBD system Target) | DRUG | Phase PHASE2 | Fragile X Syndrome | NOT_YET_RECRUITING | NCT06261450 |
| Non-investigational surgery | PROCEDURE | Phase PHASE1 | Locally Advanced Soft Tissue Sarcoma | WITHDRAWN | NCT06217536 |
| Vyxeos liposomal | DRUG | Preclinical | Acute Myeloid Leukemia (AML) | COMPLETED | NCT06143839 |
| Pembrolizumab | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT07176312 |
| JZP898 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06108050 |
| Ramucirumab | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT06043427 |
| JZP258 (XYWAV) | DRUG | Phase PHASE4 | Idiopathic Hypersomnia | COMPLETED | NCT05875974 |
| JZP258 | DRUG | Phase PHASE4 | Narcolepsy | COMPLETED | NCT05869773 |
| Cannabidiol Oral Solution [Epidiolex] | DRUG | Phase PHASE4 | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | ACTIVE_NOT_RECRUITING | NCT05864846 |
| Epidiolex | DRUG | Preclinical | Maternal Complications | RECRUITING | NCT06113237 |
| JZP541 | DRUG | Phase PHASE2 | Irritability Associated With Autism Spectrum Disorder | WITHDRAWN | NCT05733390 |
| MHA | DRUG | Phase PHASE2 | Myeloid Neoplasm | ACTIVE_NOT_RECRUITING | NCT05656248 |
| JZP441 | DRUG | Phase PHASE1 | Narcolepsy | TERMINATED | NCT06961266 |
| Suvecaltamide | DRUG | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05642442 |
| JZP341 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05631327 |
| Nabiximols-matched placebo | DRUG | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| Temozolomide | DRUG | Phase PHASE2 | Glioblastoma | RECRUITING | NCT05629702 |
| avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin | DRUG | Phase PHASE2 | Metastatic Cancer | WITHDRAWN | NCT05574504 |
| JZP815 | DRUG | Phase PHASE1 | Advanced Cancer | RECRUITING | NCT05557045 |
| Radiotherapy | RADIATION | Phase PHASE1 | Locally Advanced Soft Tissue Sarcoma | WITHDRAWN | NCT06217536 |
| Everolimus | DRUG | Phase PHASE3 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05476939 |
| CPX-315 | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05260528 |
| Cytarabine and Idarubicin | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | RECRUITING | NCT05260528 |
| Palliative Radiation Therapy | RADIATION | Phase PHASE1 | Extensive Stage Lung Small Cell Carcinoma | RECRUITING | NCT05244239 |
| Lurbinectedin 4 MG Injection [Zepzelca] | DRUG | Phase PHASE2 | Gastrointestinal Malignancies | COMPLETED | NCT05229588 |
| JZP150 | DRUG | Phase PHASE2 | Post Traumatic Stress Disorder | COMPLETED | NCT05178316 |
| JZP385 | DRUG | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05122650 |
| Etoposide | DRUG | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Carboplatin | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| Atezolizumab | DRUG | Phase PHASE1 | Endometrial Cancer | RECRUITING | NCT05542407 |
| Evorpacept | DRUG | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT05027139 |
| Gilteritinib | DRUG | Phase PHASE1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | RECRUITING | NCT05024552 |
| DNX-2401 | DRUG | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| Paxalisib | DRUG | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| Radiation Therapy | RADIATION | Phase PHASE2 | Diffuse Intrinsic Pontine Glioma | RECRUITING | NCT05009992 |
| ONC201 | DRUG | Phase PHASE2 | Meningioma | WITHDRAWN | NCT06012929 |
| CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Busulfan | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Asparaginase Erwinia Chrysanthemi (recombinant) | DRUG | Preclinical | Acute Lymphoblastic Leukemia | APPROVED_FOR_MARKETING | NCT04943952 |
| Cannabidiol (Epidiolex) | DRUG | Phase PHASE4 | Study the Efficacy of Epidiolex for Typical Absence Seizures | COMPLETED | NCT04899050 |
| Zepzelca | DRUG | Preclinical | Extensive-stage Small-cell Lung Cancer | COMPLETED | NCT04894591 |
| Transition from Xyrem to Xywav | DRUG | Preclinical | Narcolepsy | COMPLETED | NCT04803786 |
| Optional Proton (1H) MR spectroscopy (MRS) | PROCEDURE | Phase PHASE1 | Diffuse Midline Glioma (DMG) | RECRUITING | NCT04732065 |
| Standard of Care Radiation Therapy | RADIATION | Phase PHASE1 | Diffuse Midline Glioma (DMG) | RECRUITING | NCT04732065 |
| Epidiolex 100 mg/mL Oral Solution | DRUG | Phase PHASE4 | Dravet Syndrome (DS) | NOT_YET_RECRUITING | NCT06924827 |
| Solriamfetol | DRUG | Phase PHASE4 | Binge Eating Disorder | UNKNOWN | NCT04602936 |
| Zanidatamab | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | NOT_YET_RECRUITING | NCT07290985 |
| Cannabidiol (CBD) | DRUG | Phase PHASE3 | Clinical High Risk for Psychosis (CHR) | NOT_YET_RECRUITING | NCT07434973 |
| ONC206 | DRUG | Phase PHASE2 | Advanced Pheochromocytoma and Paraganglioma | RECRUITING | NCT07282587 |
| Allogeneic Hematopoietic Stem Cell Transplantation | PROCEDURE | Phase PHASE2 | Myeloid Neoplasm | ACTIVE_NOT_RECRUITING | NCT05656248 |
| Lurbinectedin | DRUG | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | NOT_YET_RECRUITING | NCT07459634 |
| Glasdegib | DRUG | Phase PHASE2 | Acute Myelogenous Leukemia (AML) Due to Therapy | ACTIVE_NOT_RECRUITING | NCT04231851 |
| Fulvestrant | DRUG | Phase PHASE2 | HER2+/HR+ Breast Cancer | COMPLETED | NCT04224272 |
| Palbociclib | DRUG | Phase PHASE2 | HER2+/HR+ Breast Cancer | COMPLETED | NCT04224272 |
| Thiotepa | DRUG | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Busulphan | DRUG | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| Vyxeos | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05558124 |
| Quality-of-Life Assessment | OTHER | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Mitoxantrone | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Recombinant Granulocyte Colony-Stimulating Factor | BIOLOGICAL | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Cladribine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04195945 |
| Track 2 | BEHAVIORAL | Approved | Daytime Sleepiness | COMPLETED | NCT04176042 |
| Track 1 | BEHAVIORAL | Approved | Daytime Sleepiness | COMPLETED | NCT04176042 |
| IV JZP-458 | DRUG | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04145531 |
| IM JZP-458 | DRUG | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04145531 |
| Enasidenib | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04075747 |
| Midostaurin | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04075747 |
| Gemcitabine | DRUG | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Bevacizumab | DRUG | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT05636111 |
| Oxaliplatin | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | NOT_YET_RECRUITING | NCT07290985 |
| Leucovorin | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | NOT_YET_RECRUITING | NCT07290985 |
| Fluorouracil | DRUG | Phase PHASE2 | Gastroesophageal Adenocarcinoma | NOT_YET_RECRUITING | NCT07290985 |
| Cisplatin | DRUG | Phase PHASE3 | Biliary Tract Cancer | RECRUITING | NCT06282575 |
| Gemtuzumab Ozogamicin | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05558124 |
| Liposome-encapsulated Daunorubicin-Cytarabine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | TERMINATED | NCT04526288 |
| Enasidenib Mesylate | DRUG | Phase PHASE2 | Recurrent Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03825796 |
| Research bone marrow aspirate | PROCEDURE | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| Research blood draw | PROCEDURE | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| Research skin biopsy | PROCEDURE | Phase PHASE1 | Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | NCT03572764 |
| Placebo Oral Solution | DRUG | Phase PHASE3 | Idiopathic Hypersomnia | COMPLETED | NCT03533114 |
| Haplo-Cord Stem Cell Transplantation | BIOLOGICAL | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| Rabbit Anti-Human T-Lymphocyte Globulin | DRUG | Phase PHASE1 | Myelodysplastic Syndromes | COMPLETED | NCT03393611 |
| Melphalan | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Standard of Care | DRUG | Phase PHASE2 | Graft-versus-host Disease | COMPLETED | NCT03339297 |
| Matched Placebo | DRUG | Phase PHASE2 | Autism Spectrum Disorder | RECRUITING | NCT03202303 |
| Cannabidivarin | DRUG | Phase PHASE2 | Autism Spectrum Disorder | RECRUITING | NCT03202303 |
| CX-8998 | DRUG | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT03436953 |
| JZP-258 | DRUG | Phase PHASE4 | Narcolepsy | COMPLETED | NCT04794491 |
| Tucatinib | DRUG | Phase PHASE1 | HER2-expressing Cancers | COMPLETED | NCT02892123 |
| Vinorelbine | DRUG | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Capecitabine | DRUG | Phase PHASE3 | Metastatic HER2-positive Breast Cancer | RECRUITING | NCT06435429 |
| Paclitaxel | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | RECRUITING | NCT07102381 |
| ZW25 (Zanidatamab) | DRUG | Phase PHASE2 | HER2+/HR+ Breast Cancer | COMPLETED | NCT04224272 |
| Best Supportive Care | OTHER | Phase PHASE3 | Veno-occlusive Disease | COMPLETED | NCT02851407 |
| Fludarabine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT04982354 |
| Erwinia Chrysanthemi asparaginase | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | WITHDRAWN | NCT02647190 |
| GWP42003-P 20 mg/kg/Day Dose | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT02565108 |
| Clobazam | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT02565108 |
| Control (placebo) | DRUG | Phase PHASE2 | Opiate Addiction | COMPLETED | NCT02539823 |
| CBD 800 mg | DRUG | Phase PHASE2 | Opiate Addiction | COMPLETED | NCT02539823 |
| CBD 400 mg | DRUG | Phase PHASE2 | Opiate Addiction | COMPLETED | NCT02539823 |
| Thioguanine | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Dexamethasone acetate | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Doxorubicin | DRUG | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Mercaptopurine | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Cyclophosphamide | DRUG | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Methotrexate | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Rituximab | BIOLOGICAL | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Ofatumumab | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| PEG asparaginase | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT02419469 |
| Prednisone | DRUG | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Vincristine | DRUG | Phase PHASE2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | RECRUITING | NCT06738368 |
| Placebo oral tablet | DRUG | Phase PHASE3 | Obstructive Sleep Apnea | COMPLETED | NCT02348606 |
| JZP-110 | DRUG | Phase PHASE2 | Excessive Sleepiness | COMPLETED | NCT03037203 |
| Cannabidiol | DRUG | Phase PHASE1 | Early Life Adversity | RECRUITING | NCT07278505 |
| Sativex® and fluconazole concomitantly (Treatment B) | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02325011 |
| Sativex® (Treatment A) | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02325011 |
| Dummy oromucosal | DRUG | Phase PHASE2 | Pain, Postoperative | RECRUITING | NCT02283281 |
| Tetrahydrocannabinol | DRUG | Phase PHASE2 | Pain, Postoperative | RECRUITING | NCT02283281 |
| pegcrisantaspase | DRUG | Phase PHASE2 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02257684 |
| Placebo Control | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT02365610 |
| GWP42003-P | DRUG | Phase PHASE3 | Seizures Associated With EMAS | TERMINATED | NCT05288283 |
| Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) | DRUG | Phase PHASE2 | Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | WITHDRAWN | NCT02150928 |
| GWP42003-P 20 mg/kg/day Dose | DRUG | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224690 |
| GWP42003-P 10 mg/kg/day Dose | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT02091206 |
| Placebo control | DRUG | Phase PHASE3 | Epilepsy | COMPLETED | NCT02224560 |
| GWP42003-P 5 mg/kg/day Dose | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT02091206 |
| GWP42006 | DRUG | Phase PHASE2 | Autism Spectrum Disorder | TERMINATED | NCT03849456 |
| Ziconotide | DRUG | Preclinical | Patients With Severe Chronic Pain | COMPLETED | NCT01888120 |
| External Beam Radiotherapy | RADIATION | Phase PHASE2 | Metastatic Osteosarcoma | TERMINATED | NCT01886105 |
| Autologous Stem Cell Infusion | OTHER | Phase PHASE2 | Metastatic Osteosarcoma | TERMINATED | NCT01886105 |
| Sm-EDTMP | DRUG | Phase PHASE2 | Metastatic Osteosarcoma | TERMINATED | NCT01886105 |
| 7+3 (cytarabine and daunorubicin) | DRUG | Phase PHASE3 | High Risk Acute Myeloid Leukemia | COMPLETED | NCT01696084 |
| asparaginase Erwinia chrysanthemi | DRUG | Phase PHASE2 | Acute Lymphoblastic Leukemia | COMPLETED | NCT01643408 |
| GW-1000-02 | DRUG | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01610713 |
| mPEG-r-crisantaspase | BIOLOGICAL | Phase PHASE1 | Hematologic Malignancies | COMPLETED | NCT01551524 |
| ADX-N05 | DRUG | Phase PHASE2 | Narcolepsy | COMPLETED | NCT01681121 |
| Bicarbonate de sodium | DRUG | Phase PHASE2 | Hematologic Disease | COMPLETED | NCT01426295 |
| Custodiol | DRUG | Phase PHASE3 | Coronary Artery Stenosis | COMPLETED | NCT01401140 |
| St Thomas | DRUG | Phase PHASE3 | Coronary Artery Stenosis | COMPLETED | NCT01401140 |
| Placebo (GA-0034) | DRUG | Phase PHASE3 | Pain | COMPLETED | NCT01424566 |
| Nabiximols | DRUG | Phase PHASE2 | NMO Spectrum Disorder | WITHDRAWN | NCT05974293 |
| Marinol | DRUG | Phase PHASE1 | Evaluation of Abuse Potential of Sativex | COMPLETED | NCT01323569 |
| Sativex and omeprazole | DRUG | Phase PHASE1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | COMPLETED | NCT01323465 |
| Sativex and ketoconazole | DRUG | Phase PHASE1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | COMPLETED | NCT01323465 |
| Sativex and rifampicin | DRUG | Phase PHASE1 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | COMPLETED | NCT01323465 |
| Placebo spray and moxifloxacin | DRUG | Phase PHASE1 | Effects of Sativex on ECG | COMPLETED | NCT01322139 |
| Sativex spray and oral moxifloxacin placebo | DRUG | Phase PHASE1 | Effects of Sativex on ECG | COMPLETED | NCT01322139 |
| Placebo spray and oral moxifloxacin placebo | DRUG | Phase PHASE1 | Effects of Sativex on ECG | COMPLETED | NCT01322139 |
| GWP42004 | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02053272 |
| GWP42003 | DRUG | Phase PHASE2 | Schizophrenia | COMPLETED | NCT02006628 |
| Caphosol | DEVICE | Phase PHASE2 | Hematologic Disease | COMPLETED | NCT01426295 |
| Intensive Salvage Therapy | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT00822094 |
| Sodium Oxybate Oral Solution (6 grams) | DRUG | Phase PHASE3 | Fibromyalgia | COMPLETED | NCT00803023 |
| Sodium Oxybate & 8 Tablets | DRUG | Phase PHASE3 | Fibromyalgia | COMPLETED | NCT00803023 |
| Sodium Oxybate & 6 Tablets | DRUG | Phase PHASE3 | Fibromyalgia | COMPLETED | NCT00803023 |
| Daunorubicin | DRUG | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT03897127 |
| Cytarabine | DRUG | Phase PHASE2 | Acute Myeloid Leukaemia | UNKNOWN | NCT04217278 |
| CPX-351 | DRUG | Phase PHASE2 | Myeloid Neoplasm | ACTIVE_NOT_RECRUITING | NCT05656248 |
| GW-2000-02 | DRUG | Phase PHASE3 | Pain | COMPLETED | NCT01606189 |
| CPX-351 (Cytarabine:Daunorubicin) Liposome Injection | DRUG | Phase PHASE1 | Hematologic Neoplasms | COMPLETED | NCT00389428 |
| Modafinil (Placebo) | DRUG | Phase PHASE3 | Narcolepsy | COMPLETED | NCT00066170 |
| Modafinil at established dose | DRUG | Phase PHASE3 | Narcolepsy | COMPLETED | NCT00066170 |
| Xyrem Placebo | DRUG | Phase PHASE3 | Narcolepsy | COMPLETED | NCT00066170 |
| Xyrem | DRUG | Phase PHASE3 | Narcolepsy With Cataplexy | COMPLETED | NCT02221869 |
| Sativex | DRUG | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01964547 |
| Erwinase | DRUG | Phase PHASE2 | Hematologic Malignancy | WITHDRAWN | NCT02718755 |
| THC Alone | DRUG | Phase PHASE3 | Palliative Care | COMPLETED | NCT00674609 |
| Sativex® | DRUG | Preclinical | Multiple Sclerosis | COMPLETED | NCT02073474 |
| tetracaine gel | DRUG | Phase PHASE4 | Healthy | WITHDRAWN | NCT00670696 |
| Rapydan | DRUG | Phase PHASE4 | Healthy | WITHDRAWN | NCT00670696 |
| Clonazepam | DRUG | Phase PHASE2 | Epilepsy | COMPLETED | NCT00594945 |
| Erwinia L-asparaginase | DRUG | Preclinical | Leukemia, Acute Lymphoblastic | NO_LONGER_AVAILABLE | NCT00590915 |
| sodium oxybate | DRUG | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT00641186 |
| Sodium Oxybate | DRUG | Phase PHASE4 | REM Sleep Behavior Disorder | COMPLETED | NCT04006925 |
| placebo | DRUG | Phase PHASE3 | Fibromyalgia | COMPLETED | NCT00423813 |
| Xyrem® | DRUG | Phase PHASE3 | Fibromyalgia | COMPLETED | NCT00423813 |
| CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection | DRUG | Phase PHASE2 | Colorectal Neoplasms | COMPLETED | NCT00361842 |
| Defibrotide | DRUG | Phase PHASE2 | Transplant-Associated Thrombotic Microangiopathy | WITHDRAWN | NCT06182410 |
| a benzodiazepine drug | DRUG | Phase PHASE3 | Anxiety Disorder | COMPLETED | NCT00106860 |
| experimental anti-anxiety drug | DRUG | Phase PHASE3 | Anxiety Disorder | COMPLETED | NCT00097708 |
| Placebo | DRUG | Phase PHASE3 | Clinical High Risk for Psychosis (CHR) | NOT_YET_RECRUITING | NCT07434973 |
| Xyrem (sodium oxybate) oral solution | DRUG | Phase PHASE3 | Narcolepsy | COMPLETED | NCT00132873 |
| Placebo (P) | DRUG | Phase PHASE4 | Obstructive Sleep Apnea Syndrome | COMPLETED | NCT00086281 |
| Modafinil (M) | DRUG | Phase PHASE4 | Obstructive Sleep Apnea Syndrome | COMPLETED | NCT00086281 |
| Zolpidem (Z) | DRUG | Phase PHASE4 | Obstructive Sleep Apnea Syndrome | COMPLETED | NCT00086281 |
| Xyrem (X) | DRUG | Phase PHASE4 | Obstructive Sleep Apnea Syndrome | COMPLETED | NCT00086281 |
| defibrotide | DRUG | Phase PHASE2 | Veno-occlusive Disease | COMPLETED | NCT00003966 |
Total products: 1120